Group 1 - The core point of the article is that 圣诺医药-B (02257) experienced a significant stock price increase, rising over 5% in the afternoon trading session, with a current price of 19.46 HKD and a trading volume of 32.44 million HKD [1] - 圣诺医药-B received a substantial investment from Bloomage Biotechnology (Hong Kong) Limited and its affiliates, acquiring 11.57 million shares valued at approximately 139 million HKD [1] - 华熙生物, through its wholly-owned subsidiary, subscribed to the strategic placement of shares in 圣诺医药 at a price of 12 HKD per share, amounting to about 138 million HKD, resulting in 华熙生物 holding approximately 9.44% of 圣诺医药's total equity post-placement [1] Group 2 - 华熙生物 plans to leverage 圣诺医药's leading advantages in RNAi technology and PNP platform to explore the industrialization of small nucleic acid drugs in targeted fat reduction [1] - The collaboration will focus on discussing clinical development and commercial cooperation for the STP705 targeted fat reduction project, accelerating the layout in the aesthetic medicine sector [1]